Literature DB >> 10830245

Fas ligand-transfected myoblasts and islet cell transplantation.

S E Turvey1, V Gonzalez-Nicolini, C I Kingsley, A T Larregina, P J Morris, M G Castro, P R Lowenstein, K J Wood.   

Abstract

BACKGROUND: Expression of Fas ligand (FasL, CD95L) within the local environment of an allograft may protect from rejection by inducing apoptosis of infiltrating T cells. However, there is mounting evidence that ectopic expression of FasL stimulates an inflammatory response and targets the FasL-expressing tissue for destruction. Given the potential therapeutic applicability of FasL-based immune protection, we sought to determine whether ectopic FasL expression was detrimental and to analyze the inflammatory response induced by ectopic FasL expression in the absence of any confounding allo-immune responses. METHODS AND
RESULTS: Two myoblast cell lines expressing different levels of functional FasL were produced. Co-implantation of FasL-expressing myoblasts with syngeneic islets allowed examination of the inflammatory response induced by ectopic FasL expression. In contrast to the suggested benefits of localized FasL expression, islets co-implanted with FasL-expressing myoblasts were destroyed in a vigorous inflammatory response predominated by neutrophils. Interestingly, FasL expression also had a marked anti-tumor effect.
CONCLUSIONS: Unless FasL-dependent neutrophil-mediated inflammation can be prevented, it is unlikely that this strategy will be useful for preventing allograft rejection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10830245     DOI: 10.1097/00007890-200005150-00043

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Neutrophils mediate parenchymal tissue necrosis and accelerate the rejection of complete major histocompatibility complex-disparate cardiac allografts in the absence of interferon-gamma.

Authors:  Masayoshi Miura; Tarek El-Sawy; Robert L Fairchild
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

2.  Attenuation of GVHD for allo-bone marrow transplantation recipient by FasL-Fas pathway in an H-2 haplotype disparate mouse combination.

Authors:  Lingbo Liu; Ping Zou; Zhongbo Hu; Zhaodong Zhong; Juan Xiao; Rong Guo; Zhiliang Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2004

3.  Characteristics of the early immune response following transplantation of mouse ES cell derived insulin-producing cell clusters.

Authors:  Ashleigh S Boyd; Kathryn J Wood
Journal:  PLoS One       Date:  2010-06-04       Impact factor: 3.240

Review 4.  Life in the Fas lane: differential outcomes of Fas signaling.

Authors:  Elizabeth Brint; Grace O'Callaghan; Aileen Houston
Journal:  Cell Mol Life Sci       Date:  2013-04-12       Impact factor: 9.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.